Relmada Therapeutics
RLMD
RLMD
78 hedge funds and large institutions have $246M invested in Relmada Therapeutics in 2025 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 8 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
77% more funds holding
Funds holding: 44 → 78 (+34)
46.11% more ownership
Funds ownership: 23.32% → 69.43% (+46%)
Holders
78
Holding in Top 10
2
Calls
$1.94M
Puts
$57K
Top Buyers
| 1 | +$24.4M | |
| 2 | +$14.3M | |
| 3 | +$9.78M | |
| 4 |
O
OrbiMed
New York
|
+$8.75M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$6.43M |
Top Sellers
| 1 | -$281K | |
| 2 | -$187K | |
| 3 | -$115K | |
| 4 |
RC
RBF Capital
San Francisco,
California
|
-$77.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$61.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SS
76
SBI Securities
Tokyo,
Japan
| $275 |
|
|||
77
Osaic Holdings
Scottsdale,
Arizona
| $24 |
|
|||
|
FRA
78
Front Row Advisors
Tiburon,
California
| $10 |
|
|||
|
TRCT
79
Tower Research Capital (TRC)
New York
| – |
|